NVGN Key Stats
- Novogen ((NVGN) Achieves Milestone with Trx-1 on Ovarian Cancer Street Insider 03/18 08:07 ET
- 8:05 am Novogen and CanTx experimental drug, Trx-1, proves effective in vivo Yahoo 03/18 08:05 ET
- Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Yahoo 03/18 08:00 ET
- Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York PR Newswire 03/12 11:00 ET
- Novogen Selected to Present at Cavendish Global Health Impact Forum PR Newswire 03/10 13:28 ET
- Novogen (NVGN) Announces Three Board Appointments, Names One Advisor Street Insider 03/04 16:30 ET
- Novogen appoints David Gryska as strategic advisor Yahoo 03/04 06:10 ET
- Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence PR Newswire] - NASDAQ:NVGN 03/04 06:00 ET
- Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform Other 02/03 12:30 ET
- Novogen to Host Corporate Update and Webcast Other 01/30 18:54 ET
|Nov 15||Misc||AGM Event for Novogen Limited|
NVGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novogen is down 18.12% over the last year vs S&P 500 Total Return up 21.54%, AstraZeneca up 39.09%, and ntercept Pharmaceuticals up 674.2%.
Balance Sheet View Statement
Y-Ratings for NVGN
Portfolio Strategies Featuring NVGN
Did Novogen make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Headquarters Country: Australia
- Headquarters State/Province: N/A
- Incorporation Country: Australia
- Incorporation State/Province: N/A
- Est. Current Fiscal Quarter End: June 30, 2014
- Est. Current Fiscal Year End: June 30, 2014
- Last Fiscal Quarter End: N/A
- Last Fiscal Year End: N/A
Novogen Ltd., is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose.